Welcome to our dedicated page for Ligand Pharma news (Ticker: LGND), a resource for investors and traders seeking the latest updates and insights on Ligand Pharma stock.
Ligand Pharmaceuticals Inc. reports developments in its biopharmaceutical royalty aggregation and technology-licensing business. The company partners with pharmaceutical and biotechnology companies, funds late-stage clinical development programs in exchange for long-term economic interests, and manages royalty interests across development- and commercial-stage therapeutic assets.
Recurring LGND news includes operating and financial results, royalty revenue drivers, material agreements, capital-structure updates, and partner clinical or regulatory events tied to products in the portfolio. Company updates also cover proprietary technologies such as Captisol® and NITRICIL™, business-development activity, and portfolio assets such as FILSPARI® where Ligand has an economic interest.
Ligand (Nasdaq: LGND) reported Q1 2026 results with total revenue $51.7M and royalty revenue $43.0M (up 56% YoY). GAAP net loss was $13.3M; adjusted net income was $34.6M or $1.63 per diluted share. Cash and short-term investments were $779.4M at March 31, 2026. Ligand reaffirmed 2026 guidance: adjusted EPS ~$8.50–$9.50 and royalty revenue $225M–$250M, reflecting anticipated partial-year contribution from the pending XOMA acquisition, expected to close in Q3 2026, subject to customary conditions.
Ligand (Nasdaq: LGND) will have senior management participate in multiple investor conferences in May 2026, including virtual and in-person events. Management will give fireside chats and host one-on-one meetings at H.C. Wainwright, Bank of America, CJS Securities, RBC, Craig-Hallum, Benchmark, and others.
Investors seeking one-on-one meetings should contact their conference or broker representative to arrange sessions.
Ligand (Nasdaq: LGND) agreed to acquire XOMA Royalty for $39.00 per share, ~$739 million equity value, plus one non-transferable CVR per share tied to ongoing litigation. The deal expands Ligand's royalty portfolio to >200 assets, adds seven marketed products and is expected to close in Q3 2026.
Ligand raised 2026 guidance: revenue to $270–$310M, royalties to $225–$250M, and adjusted EPS to $8.50–$9.50; Ligand expects the transaction to be accretive by $1.50 to adjusted EPS in 2027.
Ligand (Nasdaq: LGND) will report first quarter 2026 financial results on Thursday, May 7, 2026. A conference call will begin at 8:30 a.m. Eastern to discuss results and provide a business update. Live webcast and replay will be available via the company’s webcast link.
Dial-in details include U.S. local, toll-free and international numbers with Meeting ID 304603090.
Ligand (Nasdaq: LGND) said partner Travere Therapeutics received full FDA approval on April 14, 2026 for FILSPARI (sparsentan) to reduce proteinuria in adults and children aged 8+ with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. Ligand is entitled to a 9% royalty on worldwide net sales. In Travere’s Phase 3 DUPLEX trial, FILSPARI cut proteinuria by 48% vs 27% for irbesartan in non‑nephrotic patients at Week 108 and showed a 1.1 mL/min/1.73 m2 eGFR benefit.
Ligand (Nasdaq: LGND) on March 26, 2026 announced senior hires to expand its investments and business development team. The company named Peter Renehan, MD and Lee Brown as Vice Presidents of Investments and Business Development and promoted Lauren Hay to Vice President of Portfolio Strategy and Investments.
All three will focus on sourcing and executing royalty financing opportunities and managing Ligand’s existing portfolio, reporting to Paul Hadden and supporting long‑term value creation for shareholders.
Ligand (Nasdaq: LGND) said senior management will attend three investor conferences in March 2026, offering one-on-one meetings and two public presentations. Presentations are scheduled at the 38th Annual ROTH Conference on March 23, 2026 at 1:00 p.m. PT and the Nordic-American Healthcare Conference on March 25, 2026 at 3:45 p.m. ET. Investors may request one-on-one meetings through their Leerink, ROTH, or NAHC representative.
Ligand (Nasdaq: LGND) reported strong fourth-quarter and full-year 2025 results with total revenues of $59.7M (Q4) and $268.1M (2025). Full-year royalty revenue grew 48%, to $161.0M. GAAP net income was $124.5M for 2025; core adjusted net income was $165.1M or $8.13 per diluted share. The company reaffirmed 2026 guidance: $245M–$285M revenue and adjusted EPS of $8.00–$9.00. Cash, cash equivalents and short-term investments totaled $733.5M as of December 31, 2025.
Key commercial and clinical updates include regulatory filings, positive Phase 3/2 readouts across partnered programs, and recent transactions affecting contract revenue and royalties.
Ligand (Nasdaq: LGND) will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, and will host a conference call at 8:30 a.m. ET with live webcast and replay available.
The company described its asset-light royalty and technology licensing model, highlighted Captisol and NITRICIL platforms, and urged investors to monitor its investor relations website and X for material disclosures.
Ligand (Nasdaq: LGND) announced that CEO Todd Davis and CFO Tavo Espinoza will participate in a virtual fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026 at 10:00 a.m. Eastern Time.
Management is also scheduled for one-on-one investor meetings during the conference; investors should contact their Oppenheimer representative to arrange meetings.